Canada markets closed

LSL Pharma Group Inc. (LSL.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.4000+0.0150 (+3.90%)
At close: 03:16PM EDT
Full screen
Previous Close0.3850
Open0.4000
Bid0.3900 x N/A
Ask0.4000 x N/A
Day's Range0.3850 - 0.4000
52 Week Range0.3500 - 0.7300
Volume85,000
Avg. Volume34,294
Market Cap39.408M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0500
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    LSL Pharma Group Secures $6.44 Million as the First Closing of Concurrent Non-Brokered Private Placements

    $2.7M cash investments secured including $0.4M from Insiders $3.75M of Debt converted BOUCHERVILLE, Quebec, March 19, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC. (TSXV: LSL) (the "Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical company, today announced the closing on March 18, 2024 of non-brokered private placements for $6.44 million representing the first closing of the $8.0 million combined financings announced on March 7, 2024 (the “Financing”). Pursuant to the Financin

  • GlobeNewswire

    LSL Pharma Group Announces a Combination of Private Placements for Maximum Aggregate Gross Proceeds of $8 Million

    Up to $3.5 M in cash proceedsUp to $4.5 M in debts conversion Proceeds to be used to further expand production capacity BOUCHERVILLE, Québec, March 07, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC. (TSXV: LSL) (the "Corporation" or "LSL Pharma "), a Canadian integrated pharmaceutical company, today announced the launch of a non-brokered private placement financing of Units (as defined hereinafter) for minimum gross proceeds of $2.5 million and a maximum of $3.5 million (the “Financing”) and tha

  • GlobeNewswire

    LSL Pharma Group Announces an Extension of its Convertible Debentures Offering

    BOUCHERVILLE, Québec, Jan. 08, 2024 (GLOBE NEWSWIRE) -- LSL Pharma Group Inc. (TSXV: LSL) – (the “Company” or “LSL Pharma Group”), a Canadian integrated pharmaceutical company, announces that it extends until February 7, 2024 its brokered private placement through the issuance of unsecured convertible debentures at a price of $10 per debenture (the “Offering”). As announced on December 8, 2023, LSL Pharma Group has now raised total gross proceeds of $3,288,000 under the Offering out of a maximum